Kearbey J D, Wu D, Gao W, Miller D D, Dalton J T
Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
Xenobiotica. 2004 Mar;34(3):273-80. doi: 10.1080/0049825041008962.
1: S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide (also known as S-4) is a non-steroidal selective androgen receptor modulator demonstrating tissue-selective androgenic and anabolic effects. The purpose of the present study was to examine the systemic pharmacokinetics, elimination and oral bioavailability of S-4 in rats. 2: Thirty-five male Sprague-Dawley rats weighing approximately 250 g were randomly assigned to one of seven treatment groups. Intravenous doses of 0.5, 1, 10, and 30 mg kg(-1) were given via a jugular catheter. Oral doses of 1, 10 and 30 mg kg(-1) were administered via gavage. Plasma concentrations were determined using a validated high-performance liquid chromatography or by a high-performance liquid chromatography/mass spectrometry method. 3: Clearances ranged between 1.0 and 2.1 ml min(-1) kg(-1) and varied with dose. The volume of distribution was approximately 0.448 l kg(-1) in all treatment groups. Oral bioavailability was also dose dependent, with the lower doses showing complete oral bioavailability. The half-life of S-4 over the dose range tested was between 2.6 and 5.3 h. 4: It was demonstrated that S-4 is rapidly absorbed, slowly cleared, and has a moderate volume of distribution in rats. The pharmacokinetics and oral bioavailability of S-4 indicate that it is an excellent candidate for clinical development.
1: S-3-(4-乙酰氨基-苯氧基)-2-羟基-2-甲基-N-(4-硝基-3-三氟甲基-苯基)-丙酰胺(也称为S-4)是一种非甾体选择性雄激素受体调节剂,具有组织选择性雄激素和合成代谢作用。本研究的目的是考察S-4在大鼠体内的全身药代动力学、消除情况及口服生物利用度。2: 35只体重约250 g的雄性Sprague-Dawley大鼠被随机分配到七个治疗组之一。通过颈静脉导管给予静脉注射剂量0.5、1、10和30 mg·kg⁻¹。通过灌胃给予口服剂量1、10和30 mg·kg⁻¹。使用经过验证的高效液相色谱法或高效液相色谱/质谱法测定血浆浓度。3: 清除率在1.0至2.1 ml·min⁻¹·kg⁻¹之间,随剂量变化。所有治疗组的分布容积约为0.448 l·kg⁻¹。口服生物利用度也呈剂量依赖性,较低剂量显示完全口服生物利用度。在所测试的剂量范围内,S-4的半衰期在2.6至5.3小时之间。4: 结果表明,S-4在大鼠体内吸收迅速、清除缓慢且分布容积适中。S-4的药代动力学和口服生物利用度表明它是临床开发的优秀候选药物。